Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib

BACKGROUND AND AIMS: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. RESULTS: 442 patients with advanced stage HCC on sorafenib were recruited (foll...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Howell, Jessica A., Pinato, David J., Ramaswami, Ramya, Arizumi, Tadaaki, Ferrari, Carlotta, Gibbin, Antonello, Burlone, Michela E., Guaschino, Giulia, Toniutto, Pierluigi, Black, James, Sellers, Laura, Kudo, Masatoshi, Pirisi, Mario, Sharma, Rohini
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482646/
https://ncbi.nlm.nih.gov/pubmed/28212535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15322
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller